Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ISIS 3521/CGP64128A antisense blocker of protein kinase C alpha data

Phase I testing has shown some remissions with side effects at higher doses that should be

Read the full 162 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE